Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Dr. Reddy’s Q3 and 9M FY16 Financial Results
February 9, 2016 4:55 AM EST
Q3 Revenues at Rs. 39.7 billion (YoY growth of 3%)
Q3
EBITDA at Rs. 10.1 billion (25.5% of the revenues)
9M Revenues at Rs. 117.1 billion (YoY growth of 7%)
9M
EBITDA at Rs. 31.4 billion (26.8% of the revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the quarter ended December 31, 2015 under International Financial Reporting Standards (IFRS).
Q3 FY16: Key Highlights
Consolidated revenues at Rs. 39.7 billion, year-on-year growth of 3%.... More